Human Polyclonal FABP4 Ab
- Known as:
- Human Polyclonal FABP4 Antibody
- Catalog number:
- a0232
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- ABclonal
- Gene target:
- Human Polyclonal FABP4
Related genes to: Human Polyclonal FABP4 Ab
- Gene:
- FABP4 NIH gene
- Name:
- fatty acid binding protein 4
- Previous symbol:
- -
- Synonyms:
- A-FABP, aP2
- Chromosome:
- 8q21.13
- Locus Type:
- gene with protein product
- Date approved:
- 1991-08-06
- Date modifiied:
- 2016-01-18
Related products to: Human Polyclonal FABP4 Ab
Related articles to: Human Polyclonal FABP4 Ab
- Lipid metabolism and its regulatory molecules, especially adipokines, have gained significant attention in recent pathogenesis research of autism spectrum disorder (ASD). - Source: PubMed
Publication date: 2026/06/22
Abdelaziz Asmaa WafeeqAlkherkhisy Mohammad MostafaEl-Sheikh Heba-Allah RamadanElhamid Salwa Amin Abd - - Source: PubMed
Publication date: 2026/06/22
Liu QiTian YanjunLi GuijunZhang ShengGao YangxuMa XiaoyanSu ZeliFan WeiningLi Hongping - Cutaneous fibrosis - encompassing keloids, hypertrophic scars, localized scleroderma (morphea), and scarring alopecias - remains fundamentally undertreated, with conventional interventions frequently yielding incomplete therapeutic responses and high rates of recurrence. Pioglitazone, a Food and Drug Administration (FDA)-approved peroxisome proliferator-activated receptor γ (PPAR-γ) agonist traditionally utilized for glycemic control in type 2 diabetes mellitus, represents a highly compelling candidate for dermatologic repurposing. Beyond its canonical metabolic functions, robust target engagement of PPAR-γ by pioglitazone suppresses NF-κB-driven cytokine cascades, directly inhibits NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome assembly, promotes macrophage polarization toward tissue-reparative phenotypes, and disrupts profibrotic TGF-β/SMAD signaling architectures. Consequently, the drug exerts a dual mechanism of action, simultaneously attenuating chronic inflammation while inhibiting pathological fibrogenesis. This review expands upon prior analyses by integrating recently published clinical and scientific data, specifically highlighting new translational milestones, including human registry data in progeroid syndromes and randomized controlled trials in cicatricial alopecia. A distinct focus is placed on advancements in localized delivery strategies, such as nanostructured lipid carriers and niosomes, that offer the potential to overcome pioglitazone's inherent physicochemical constraints and thereby maximize dermal target engagement while avoiding systemic toxicities like heart failure and bladder cancer. Furthermore, this analysis synthesizes recent molecular insights connecting fibrosis and inflammation via target engagement biomarkers (e.g., FABP4, CD36) and proposes actionable, biomarker-driven trial designs, including adaptive basket trials, to bridge current gaps in dermatology-specific translation. Demonstrating localized anti-fibrotic and anti-inflammatory efficacy with minimal systemic risk could establish pioglitazone as a mechanism-based, disease-modifying therapy for a broad spectrum of fibrotic and scarring dermatologic disorders. - Source: PubMed
Publication date: 2026/06/02
Steevens NolanKeller KathrynBroughton LukeStegura CarolBeck Tyler CValdebran Manuel A - Microwave ablation induces heating of tissue. High energy results in thermal cell death, but low energy treatment without tissue necrosis has been shown to induce cutaneous immunity in an HPV wart model. It is approved as an effective cancer treatment for solid organ cancers, and therefore it is of interest to know if microwave delivered directly to the skin holds potential for treatment of skin cancer. This pilot study focused on transcriptomic profiling of cutaneous melanoma metastases to investigate molecular changes associated with microwave therapy. Seven adult patients with skin metastases from malignant cutaneous melanoma, not resolving on standard treatment, were recruited. Microwave energy was applied to separate melanoma metastases. Morphological, histological, and transcriptomic changes assessed via tissue RNA sequencing were evaluated. Three participants showed complete response, while four showed partial response by histological assessment. In complete responders, skin lesion RNA sequencing after treatment, compared with baseline, identified increased inflammation (CXCL5, CXCL8, IL1A, COL1A1) and downregulated cancer markers (PRAME, S100B, MLANA, STK32A). Compared with partial responders, complete responders showed enrichment of FABP4 and reduced expression of cancer markers. Microwave therapy produced local tumor responses and associated inflammatory transcriptomic changes in complete responders, supporting further clinical evaluation in cutaneous melanoma metastases. - Source: PubMed
Losol PurevsurenO'Driscoll DanielPulido Andres Vallejovon Witzleben AdrianBoukas KonstantinosSommerlad MatthewOttensmeier ChristianArdern-Jones Michael R - Pancreatic neuroendocrine tumors (PanNETs) are rare neoplasms belonging to the broader group of neuroendocrine neoplasms. Epidemiological evidence indicates that visceral obesity is associated with both an increased incidence of PanNETs and unfavorable clinicopathological features. However, the mechanisms underlying adipocyte-PanNETs interactions remain poorly understood. - Source: PubMed
Publication date: 2026/06/18
Oldani MonicaGrassi Elisa StellariaGaudenzi GermanoRybinska IlonaCarra SilviaMassardi ElenaFazio NicolaCaraglia MichelePersani LucaVitale Giovanni